The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice

AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hypercholesterolaemia and atherosclerosis. PCSK9 binds to the low density lipoprotein receptor and enhances its degradation, which leads to the reduced clearance of low dens...

Full description

Saved in:
Bibliographic Details
Published in:Eur Heart J
Main Authors: Landlinger, Christine, Pouwer, Marianne G., Juno, Claudia, van der Hoorn, José W.A., Pieterman, Elsbet J., Jukema, J. Wouter, Staffler, Guenther, Princen, Hans M.G., Galabova, Gergana
Format: Artigo
Language:Inglês
Published: Oxford University Press 2017
Subjects:
Basic Science
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5837708/
https://ncbi.nlm.nih.gov/pubmed/28637178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehx260
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items